University of Washington

Cornell University

Imclone LLC

Stephen R Plymate

Dustin James Maly

Dale Lincoln Ludwig

Wesley C Van Voorhis

Kayode K Ojo

Erkang Fan

Rama Subba Rao Vidadala

Paraskevi Giannakakou

The present disclosure is generally directed to bumped kinase inhibitor (BKI) compositions and methods for treating cancer.

Bumped kinase inhibitor compositions and methods for treating cancer

The invention relates to detection and/or treatment of a subset of prostate cancer patients who may benefit from taxane treatment. The method comprises testing whether an androgen receptor (AR) splice variant is present in a test sample obtained from the patient, wherein the androgen receptor variant can be ARv5,6,7.

Identifying taxane sensitivity in prostate cancer patients

The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.

IGF-IR antagonists as adjuvants for treatment of prostate cancer

Growing community of inventors

Seattle, WA, United States of America

Stephen R Plymate